Human Vasodilatory Effect of GLP-1
Vasodilatory Effect of GLP-1
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Waiting list for elective PCI to LAD Able to give informed consent Over 18
Exclusion Criteria:
- GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline
Time Frame: Change from baseline
|
Change in coronary microcirculatory resistance from baseline
|
Change from baseline
|
|
Forearm bloodflow ratio with GLP-1
Time Frame: Change from baseline
|
Peripheral vasodilatory response of GLP-1
|
Change from baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Aetesam-Ur-Rahman M, Zhao TX, Paques K, Oliveira J, Khialani B, Kyranis S, Braganza DM, Clarke SC, Bennett MR, West NEJ, Hoole SP. Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios. J Am Heart Assoc. 2022 May 3;11(9):e023554. doi: 10.1161/JAHA.121.023554. Epub 2022 Apr 26.
- Aetesam-Ur-Rahman M, Giblett JP, Khialani B, Kyranis S, Clarke SJ, Zhao TX, Braganza DM, Clarke SC, West NEJ, Bennett MR, Hoole SP. GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated. BMC Cardiovasc Disord. 2021 May 1;21(1):223. doi: 10.1186/s12872-021-02030-5.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14/EE/0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angina, Stable
-
NCT01331967CompletedDiabetic Stable Angina | Diabetic Unstable Angina
-
NCT03963609CompletedChronic Stable Angina
-
NCT04244812UnknownChronic Stable Angina Pectoris
-
NCT04041245Unknown
-
NCT03789552RecruitingChronic Stable Angina Pectoris
-
NCT02456402CompletedStable Angina | Unstable Angina
-
NCT04264559UnknownChronic Stable Angina Pectoris
-
NCT04041206Unknown
-
NCT02315976CompletedChronic Stable Angina Pectoris
Clinical Trials on GLP-1 (7-36)Amide
-
NCT02127996UnknownMyocardial Infarction | Angina Pectoris | Coronary Heart Disease | Reperfusion Injury
-
NCT00393445Completed
-
NCT01689051CompletedType 2 Diabetes | Blood Flow | Human Physiology | Glucagon-like Peptide-1 | Blod Pressure
-
NCT00940134Completed